Please Wait
Applying Filters...
menu
    • menu
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Oxaliplatin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 34,039Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AstraZeneca Wins CDSCO Nod for Durvalumab in Gastric Cancer
    AstraZeneca Wins CDSCO Nod for Durvalumab in Gastric Cancer

    06 Feb 2026

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/astrazeneca-gets-cdsco-approval-for-durvalumab-in-gastric-cancer-treatment/articleshow/127904949.cms

    ECONOMICTIMES
    06 Feb 2026
    Share Share
    FDA Accepts Exelixis' NDA for Zanzalintinib + ICI in Cancer
    FDA Accepts Exelixis' NDA for Zanzalintinib + ICI in Cancer

    02 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260130221586/en/Exelixis-Announces-U.S.-FDA-Accepted-the-New-Drug-Application-for-Zanzalintinib-in-Combination-with-an-Immune-Checkpoint-Inhibitor-for-Patients-with-Metastatic-Colorectal-Cancer

    BUSINESSWIRE
    02 Feb 2026
    Share Share
    Shandong’s Generics Oxaliplatin Receives Approval in US
    Shandong’s Generics Oxaliplatin Receives Approval in US

    14 Jan 2026

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219765

    FDA
    14 Jan 2026
    Share Share
    MediciNova Completes MN-166 Enrollment in CIPN Prevention Trial
    MediciNova Completes MN-166 Enrollment in CIPN Prevention Trial

    18 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/18/3207535/7767/en/MediciNova-Announces-Completion-of-Patient-Enrollment-Evaluating-MN-166-ibudilast-in-the-Prevention-of-Chemotherapy-induced-Peripheral-Neuropathy.html

    GLOBENEWSWIRE
    18 Dec 2025
    Share Share
    Az's Imfinzi Bags Perioperative Nod In Early-Stage Stomach Cancer
    Az's Imfinzi Bags Perioperative Nod In Early-Stage Stomach Cancer

    25 Nov 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/azs-imfinzi-expands-its-perioperative-prowess-early-stage-stomach-cancer-fda-nod

    FIERCE PHARMA
    25 Nov 2025
    Share Share
    Stomach Cancer Awareness Month
    Stomach Cancer Awareness Month

    01 Nov 2025

    // PRESS RELEASE

    https://www.nanoalvand.com/index.php/en/blog-en/9-news/215-stomach-cancer-awareness-month

    PRESS RELEASE
    01 Nov 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.